What adjuvant therapy would you offer a postmenopausal with a new pT2N0 HR+/HER2+ breast cancer primary who is concurrently being treated for well controlled oligometastatic HR+/HER2- who’s been on anastrozole/ribociclib?

The new primary was incidentally picked up on re-staging scans for the metastatic ER+ cancer. Would you modify the CDK4/6i and AI? What HER2 therapy would you offer?

Please select the option that best describes you:

What adjuvant therapy would you offer a postmenopausal with a new pT2N0 HR+/HER2+ breast cancer primary who is concurrently being treated for well controlled oligometastatic HR+/HER2- who’s been on anastrozole/ribociclib?

Related Questions